Welcome to our dedicated page for Precipio news (Ticker: PRPO), a resource for investors and traders seeking the latest updates and insights on Precipio stock.
Precipio, Inc. reports developments from its specialty cancer diagnostics business, which focuses on diagnostic products and services for cancer, including hematologic malignancies. Company updates commonly address performance in the Pathology Services Division and Products Division, customer and laboratory workflow trends, shareholder update calls, and balance sheet actions tied to debt, warrants, and common-stock financing arrangements.
Precipio news also covers its proprietary diagnostic technologies, including the Bloodhound BCR::ABL1 assay for Chronic Myeloid Leukemia, study publications, scientific meeting presentations, and collaborations involving clinical laboratories and cancer centers. Operational disclosures may include cybersecurity response, service continuity, and the company’s use of laboratory-developed technologies that are validated clinically and commercialized for the broader laboratory market.
Precipio (NASDAQ:PRPO) identified a single, limited unauthorized access to a specific data folder in its secure cloud file environment on Dec. 4, 2025.
Initial findings say the breach was limited to historical files in a customer service folder (operational procedures, temperature logs, vendor invoices) and did not include patient Social Security numbers, addresses, patient financial data, proprietary company data, or affect diagnostics, operations, or patient care.
The company activated incident response, engaged external cybersecurity counsel and forensic specialists, reset companywide passwords, enhanced monitoring, and reports no evidence of continued access. Precipio expects related costs to be covered by its cybersecurity insurance and currently does not anticipate material impact to operations or shareholders.
Precipio (NASDAQ: PRPO) reported Q3-2025 results on Nov 14, 2025. Revenues were $6.8M, up 30% YoY and 20% QoQ. Pathology Services revenue grew to $6.0M (+$1.0M QoQ) and Product Division sales rose to $0.72M (+16% QoQ).
Adjusted EBITDA was $469K (positive vs. $100K in Q3-2024) and operating cash flow before Change Healthcare transactions was $285K, swinging from a Q2-2025 burn of ($148K). Product gross margin fell to 30% from 44% while Pathology margin rose to 46%.
The company will hold a shareholder call on Nov 17, 2025 at 5:00 pm ET.
Precipio (NASDAQ: PRPO) will host a Q3-2025 shareholder update conference call on November 17, 2025 at 5:00 PM ET. The call will cover updates on the company’s core businesses and allow investor questions submitted in advance via email to investors@precipiodx.com. Callers can access the live call by dialing 800.717.1738 and asking for the Precipio conference call. A replay will be available about 24 hours after the call on the Investors page at https://www.precipiodx.com/investors/.
Precipio (NASDAQ:PRPO), a specialty cancer diagnostics company, has announced the termination of its At-The-Market (ATM) instrument with Alliance Global Partners (AGP). The decision reflects the company's improved financial position, marked by the elimination of negative cash flow from operations and recent increases in cash balance.
CEO Ilan Danieli emphasized that the company is now stronger and no longer needs to rely on the ATM tool for capital raises, demonstrating management's commitment to enhancing shareholder value.
Precipio (NASDAQ: PRPO) reported strong Q2-2025 financial results, with total revenues reaching $5.7M, representing a 27% YoY increase and 15% QoQ growth. The company's Pathology Services division saw an 18% QoQ increase, while Product revenues grew 23% QoQ.
Key financial metrics show significant improvement with Adjusted EBITDA of ($78K), an 87% improvement YoY, and cash used in operations decreased 71% YoY to $148K. Overall gross margins improved from 39% to 43% YoY, despite a temporary decline in Product division margins from 50% to 44% due to strategic investments in expansion.
Management expects to achieve positive cash flow and a debt-free balance sheet by year-end, following the completion of the Change Healthcare loan repayment.
Precipio (NASDAQ: PRPO), a specialty cancer diagnostics company, has scheduled its Q2-2025 shareholder update conference call for August 14th, 2025 at 5:00 PM ET. The call will provide updates on the company's core business segments.
Shareholders can access the call by dialing 800.717.1738. Questions can be submitted in advance via email to investors@precipiodx.com. A replay will be available approximately 24 hours after the call through Precipio's investor relations website.
Precipio (NASDAQ: PRPO), a specialty cancer diagnostics company, has restructured its warrant agreement with its largest warrant holder. Under the new agreement, 100,000 warrants will be exercised for cash, while the remaining 200,000 warrants will be exercised cashlessly.
The restructuring results in two key outcomes: 1) A reduction in share dilution, with total new shares decreasing from ~300,000 to ~130,000-150,000, and 2) A reduced cash inflow of $1.2 million instead of the original $3.8 million. Management will discuss this transaction during their upcoming quarterly shareholder call around August 15th, 2025.
Precipio (NASDAQ: PRPO), a specialty cancer diagnostics company, has scheduled its Q1-2025 shareholder update conference call for May 15th, 2025 at 5:00 PM ET. The call will provide updates on all of the company's core businesses.
Shareholders can access the call by dialing 844-695-5519 (international: 1-412-902-6760) or pre-register at the provided link to receive direct dial-in details. Questions can be submitted in advance via email to investors@precipiodx.com. A replay will be available approximately 24 hours after the call on Precipio's investor relations website.